<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585637</url>
  </required_header>
  <id_info>
    <org_study_id>07-342</org_study_id>
    <secondary_id>P15192</secondary_id>
    <nct_id>NCT00585637</nct_id>
  </id_info>
  <brief_title>Vitamin D for Chemoprevention</brief_title>
  <official_title>Defining Optimal Doses of Vitamin D for Chemoprevention in Blacks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help us know the effects of Vitamin D pills in Blacks. The results of this
      study may be the first step in creating ways to prevent the risks of colon and prostate
      cancer. It will also help us develop ways to reduce colon cancer and prostate cancer among
      Blacks. This study will find out if Vitamin D pills can increase Vitamin D to healthy levels
      in our bodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will be asked to answer some questions about their diet, exercise and
           health. In addition, participants blood pressure will be taken. These assessments will
           occur at baseline, 3- and 6-month appointments. At baseline only, we will measure skin
           tone with a tool called the Photovolt 577.

        -  A small blood sample will be taken to see how much Vitamin D is the body and will also
           look at levels of other markers of disease such as proteins, hormones, and genes.

        -  Participants will take a vitamin pill every day for three months and be randomly
           assigned to one of four different types of pills.

        -  Participants will be called or visited at least every two weeks. They will be asked
           questions to determine if they have any side effects associated with high levels of
           Vitamin D.

        -  At the beginning of the second and third months, participants will be provided with more
           pills. At the end of the third month, another blood sample will be taken. Three months
           after that, the final blood sample will be taken.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.</measure>
    <time_frame>Baseline, 3months, 6months</time_frame>
    <description>Among Blacks, identify a dose of oral vitamin D supplementation that will result in levels of plasma 25(OH)D that would be predicted to reduce colorectal cancer incidence. Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6 From 0 to 3 Months.</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-6 from baseline to the 3 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-10 From 0 to 3 Months.</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-10 from baseline to the 3 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sTNF-R2 From 0 to 3 Months.</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>Examine the influence of oral vitamin D supplementation on inflammatory marker sTNF-R2 from baseline to the 3 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP From 0 to 3 Months.</measure>
    <time_frame>From baseline to 3 months</time_frame>
    <description>Examine the influence of oral vitamin D supplementation on inflammatory marker CRP from baseline to the 3 month follow-up.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Gastrointestinal Cancers</condition>
  <condition>Prostate Cancer</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 IU of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 IU of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4000 IU of Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Taken orally every day for three months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill taken once daily for 3 month</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 30 and 80 years

          -  Comfortable communicating in English

          -  Currently has a primary care physician

          -  Willing to discontinue vitamin D or calcium supplements

          -  Willing to have all protocol specific tests run

        Exclusion Criteria:

          -  Plans on taking a vacation or travel to a sunny region within 3 months of vitamin
             supplementation period except for a short period (i.e. 1 weekend)

          -  Pregnant or breast feeding or planning on becoming pregnant in the following year

          -  Pre-existing calcium (including hypercalcemia), parathyroid conditions (including
             hyperparathyroidism), sarcoidosis

          -  No concurrent active malignancies (other than non-melanoma skin cancer) or previous
             diagnosis of prostate cancer

          -  Cognitively impaired

          -  Active thyroid disease (e.g. Graves, Hashimoto's or thyroiditis)

          -  History of nephrolithiasis, chronic liver disease, chronic renal disease, or renal
             dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Giovannucci, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health/Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary G Bennett, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chandler PD, Scott JB, Drake BF, Ng K, Forman JP, Chan AT, Bennett GG, Hollis BW, Giovannucci EL, Emmons KM, Fuchs CS. Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. Am J Med. 2014 Aug;127(8):772-8. doi: 10.1016/j.amjmed.2014.02.044. Epub 2014 Mar 20.</citation>
    <PMID>24657333</PMID>
  </results_reference>
  <results_reference>
    <citation>Ng K, Scott JB, Drake BF, Chan AT, Hollis BW, Chandler PD, Bennett GG, Giovannucci EL, Gonzalez-Suarez E, Meyerhardt JA, Emmons KM, Fuchs CS. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr. 2014 Mar;99(3):587-98. doi: 10.3945/ajcn.113.067777. Epub 2013 Dec 24.</citation>
    <PMID>24368437</PMID>
  </results_reference>
  <results_reference>
    <citation>Chandler PD, Scott JB, Drake BF, Ng K, Manson JE, Rifai N, Chan AT, Bennett GG, Hollis BW, Giovannucci EL, Emmons KM, Fuchs CS. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer Prev Res (Phila). 2014 Feb;7(2):218-25. doi: 10.1158/1940-6207.CAPR-13-0338-T. Epub 2013 Dec 10.</citation>
    <PMID>24327720</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>March 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Kimmie Ng, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Blacks</keyword>
  <keyword>cancer</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited community-based African American (www.clinicaltrials.gov; NCT00585637). Participants were drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>No Vitamin D</title>
          <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
        </group>
        <group group_id="P2">
          <title>1000 IU of Vitamin D</title>
          <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="P3">
          <title>2000 IU of Vitamin D</title>
          <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="P4">
          <title>4000 IU of Vitamin D</title>
          <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3-month Time Point</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>6-month Time Point</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
      <group_list>
        <group group_id="B1">
          <title>No Vitamin D</title>
          <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
        </group>
        <group group_id="B2">
          <title>1000 IU of Vitamin D</title>
          <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="B3">
          <title>2000 IU of Vitamin D</title>
          <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="B4">
          <title>4000 IU of Vitamin D</title>
          <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="83"/>
            <count group_id="B5" value="328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" lower_limit="44.2" upper_limit="58.0"/>
                    <measurement group_id="B2" value="51.1" lower_limit="43.4" upper_limit="60.1"/>
                    <measurement group_id="B3" value="50.3" lower_limit="43.4" upper_limit="58.2"/>
                    <measurement group_id="B4" value="51.3" lower_limit="44.1" upper_limit="59.7"/>
                    <measurement group_id="B5" value="51.0" lower_limit="43.6" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.</title>
        <description>Among Blacks, identify a dose of oral vitamin D supplementation that will result in levels of plasma 25(OH)D that would be predicted to reduce colorectal cancer incidence. Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</description>
        <time_frame>Baseline, 3months, 6months</time_frame>
        <population>Number of participants analyzed above is for baseline. At 3 months, number of participants analyzed was: 71 (no vitamin D), 67 (1000 IU Vitamin D), 76 (2000 IU Vitamin D) and 78 (4000 IU Vitamin D). At 6 months, number of participants analyzed was: 75 (no vitamin D), 68 (1000 IU Vitamin D), 72 (2000 IU Vitamin D) and 77 (4000 IU Vitamin D).</population>
        <group_list>
          <group group_id="O1">
            <title>No Vitamin D</title>
            <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
          </group>
          <group group_id="O2">
            <title>1000 IU of Vitamin D</title>
            <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O3">
            <title>2000 IU of Vitamin D</title>
            <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O4">
            <title>4000 IU of Vitamin D</title>
            <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.</title>
          <description>Among Blacks, identify a dose of oral vitamin D supplementation that will result in levels of plasma 25(OH)D that would be predicted to reduce colorectal cancer incidence. Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</description>
          <population>Number of participants analyzed above is for baseline. At 3 months, number of participants analyzed was: 71 (no vitamin D), 67 (1000 IU Vitamin D), 76 (2000 IU Vitamin D) and 78 (4000 IU Vitamin D). At 6 months, number of participants analyzed was: 75 (no vitamin D), 68 (1000 IU Vitamin D), 72 (2000 IU Vitamin D) and 77 (4000 IU Vitamin D).</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 25(OH)D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="10.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="16.2" lower_limit="11.0" upper_limit="22.7"/>
                    <measurement group_id="O3" value="13.9" lower_limit="9.5" upper_limit="22.3"/>
                    <measurement group_id="O4" value="15.7" lower_limit="11.0" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25(OH)D at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="7.2" upper_limit="18.6"/>
                    <measurement group_id="O2" value="29.7" lower_limit="25.6" upper_limit="32.9"/>
                    <measurement group_id="O3" value="34.8" lower_limit="28.8" upper_limit="41.0"/>
                    <measurement group_id="O4" value="45.9" lower_limit="39.4" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25(OH)D at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="12.2" upper_limit="23.3"/>
                    <measurement group_id="O2" value="21.2" lower_limit="16.8" upper_limit="27.8"/>
                    <measurement group_id="O3" value="27.0" lower_limit="20.6" upper_limit="31.1"/>
                    <measurement group_id="O4" value="31.2" lower_limit="26.5" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6 From 0 to 3 Months.</title>
        <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-6 from baseline to the 3 month follow-up.</description>
        <time_frame>From baseline to 3 months</time_frame>
        <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
        <group_list>
          <group group_id="O1">
            <title>No Vitamin D</title>
            <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
          </group>
          <group group_id="O2">
            <title>1000 IU of Vitamin D</title>
            <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O3">
            <title>2000 IU of Vitamin D</title>
            <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O4">
            <title>4000 IU of Vitamin D</title>
            <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 From 0 to 3 Months.</title>
          <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-6 from baseline to the 3 month follow-up.</description>
          <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.96" upper_limit="0.88"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-1.07" upper_limit="0.93"/>
                    <measurement group_id="O3" value="0.01" lower_limit="-0.57" upper_limit="0.89"/>
                    <measurement group_id="O4" value="0.08" lower_limit="-0.61" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-10 From 0 to 3 Months.</title>
        <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-10 from baseline to the 3 month follow-up.</description>
        <time_frame>From baseline to 3 months</time_frame>
        <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
        <group_list>
          <group group_id="O1">
            <title>No Vitamin D</title>
            <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
          </group>
          <group group_id="O2">
            <title>1000 IU of Vitamin D</title>
            <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O3">
            <title>2000 IU of Vitamin D</title>
            <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O4">
            <title>4000 IU of Vitamin D</title>
            <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-10 From 0 to 3 Months.</title>
          <description>Examine the influence of oral vitamin D supplementation on inflammatory marker IL-10 from baseline to the 3 month follow-up.</description>
          <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.06" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.08" upper_limit="0.02"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.09" upper_limit="0.02"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.06" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in sTNF-R2 From 0 to 3 Months.</title>
        <description>Examine the influence of oral vitamin D supplementation on inflammatory marker sTNF-R2 from baseline to the 3 month follow-up.</description>
        <time_frame>From baseline to 3 months</time_frame>
        <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
        <group_list>
          <group group_id="O1">
            <title>No Vitamin D</title>
            <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
          </group>
          <group group_id="O2">
            <title>1000 IU of Vitamin D</title>
            <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O3">
            <title>2000 IU of Vitamin D</title>
            <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O4">
            <title>4000 IU of Vitamin D</title>
            <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in sTNF-R2 From 0 to 3 Months.</title>
          <description>Examine the influence of oral vitamin D supplementation on inflammatory marker sTNF-R2 from baseline to the 3 month follow-up.</description>
          <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-187.75" upper_limit="160.10"/>
                    <measurement group_id="O2" value="-9.88" lower_limit="-130.28" upper_limit="149.19"/>
                    <measurement group_id="O3" value="59.16" lower_limit="-132.66" upper_limit="214.59"/>
                    <measurement group_id="O4" value="13.29" lower_limit="-137.03" upper_limit="144.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRP From 0 to 3 Months.</title>
        <description>Examine the influence of oral vitamin D supplementation on inflammatory marker CRP from baseline to the 3 month follow-up.</description>
        <time_frame>From baseline to 3 months</time_frame>
        <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
        <group_list>
          <group group_id="O1">
            <title>No Vitamin D</title>
            <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
          </group>
          <group group_id="O2">
            <title>1000 IU of Vitamin D</title>
            <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O3">
            <title>2000 IU of Vitamin D</title>
            <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
          <group group_id="O4">
            <title>4000 IU of Vitamin D</title>
            <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRP From 0 to 3 Months.</title>
          <description>Examine the influence of oral vitamin D supplementation on inflammatory marker CRP from baseline to the 3 month follow-up.</description>
          <population>Community-based African Americans drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-1.13" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.58" upper_limit="0.86"/>
                    <measurement group_id="O3" value="0.02" lower_limit="-0.68" upper_limit="1.21"/>
                    <measurement group_id="O4" value="0.03" lower_limit="-0.68" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 2 weeks, up to 6 months.</time_frame>
      <desc>Participants were assessed every 2 weeks. The table for 'Other (Non-Serious) Adverse Events' only reports on a subset of patients as calcium levels were only checked in a subset of patients. Although all patients were evaluated for adverse events, the only reported adverse event was hypercalcemia.</desc>
      <group_list>
        <group group_id="E1">
          <title>No Vitamin D</title>
          <description>No Vitamin D
Placebo: Placebo pill taken once daily for 3 month</description>
        </group>
        <group group_id="E2">
          <title>1000 IU of Vitamin D</title>
          <description>1000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="E3">
          <title>2000 IU of Vitamin D</title>
          <description>2000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
        <group group_id="E4">
          <title>4000 IU of Vitamin D</title>
          <description>4000 IU of Vitamin D
Vitamin D: Taken orally every day for three months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia at 1 month</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hypercalcemia at 3 months</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimmie Ng, MD, MPH</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-4150</phone>
      <email>Kimmie_Ng@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

